New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.60
5.09
+1.80%
Follow ABBV
Alert me
What it owns vs. what it owes Q3 FY2026, Sep 30, 2026
It owes $70.1B more in debt than it holds in cash and short-term investments. Debt has risen from $67.5B to $80.9B since Q4 FY25. Liabilities are $4.5B more than assets: shareholders’ equity is negative. What is a balance sheet?
Owns
$110.2BLong-term assets
$26.7BOther short-term assets
$10.8BCash & short-term investments
Funded by
$71.3BOther liabilities
$80.9BDebt
Debt is 54.8% of the total; liabilities are $4.5B more than assets.
Net debt has held near 47% of assets since Q4 FY25.
Net debt ÷ assets (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Total assets | $134.0B | $136.5B | $135.1B | $147.7B |
| Net debt (debt less cash) | $62.3B | $63.5B | $64.3B | $70.1B |
| Net debt ÷ assets (right axis) | 46.5% | 46.5% | 47.6% | 47.5% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
5,229.00 | 9,391.00 | 6,569.00 | 10,774.00 |
Receivables |
12,589.00 | 12,479.00 | 13,824.00 | 13,509.00 | |
Inventory |
4,951.00 | 5,049.00 | 5,127.00 | 5,305.00 | |
Total current assets |
29,062.00 | 33,529.00 | 33,669.00 | 37,480.00 | |
Property, Plant, Equpment (Net) |
5,628.00 | 5,687.00 | 5,796.00 | 5,941.00 | |
Long-Term Investments |
268.00 | 268.00 | 266.00 | 387.00 | |
Goodwill and Intangible Assets (Total) |
88,281.00 | 86,443.00 | 84,658.00 | 94,452.00 | |
Long-term assets (Other) |
10,721.00 | 10,536.00 | 10,726.00 | 9,420.00 | |
Total non-current assets |
104,898.00 | 102,934.00 | 101,446.00 | 110,200.00 | |
Total Assets |
133,960.00 | 136,463.00 | 135,115.00 | 147,680.00 | |
Accounts Payable |
34,734.00 | 33,774.00 | 33,301.00 | 34,429.00 | |
Current Part of Debt |
8,555.00 | 8,326.00 | 8,341.00 | 8,673.00 | |
Total current liabilities |
43,289.00 | 42,100.00 | 41,642.00 | 43,102.00 | |
Long Term Debt (Total) |
58,941.00 | 64,532.00 | 62,481.00 | 72,230.00 | |
Long Term Tax Liability (Deferred) |
2,389.00 | 2,332.00 | 2,277.00 | 2,223.00 | |
Non-current Liabilities (Other) |
32,569.00 | 34,111.00 | 34,603.00 | 34,663.00 | |
Total non-current liabilities |
93,899.00 | 100,975.00 | 99,361.00 | 109,116.00 | |
Total liabilities |
137,188.00 | 143,075.00 | 141,003.00 | 152,218.00 | |
Additional Paid In Capital |
22,495.00 | 22,962.00 | 23,156.00 | 23,371.00 | |
Common Stock (Net) |
18.00 | 18.00 | 18.00 | 18.00 | |
Retained Earnings |
(15,493.00) | (17,872.00) | (17,333.00) | (16,190.00) | |
Treasury Stock |
9,146.00 | 10,611.00 | 10,618.00 | 10,616.00 | |
Common Equity (Total) |
(3,228.00) | (6,612.00) | (5,888.00) | (4,538.00) | |
Shareholders Equity (Total) |
(3,228.00) | (6,612.00) | (5,888.00) | (4,538.00) | |
Shareholders Equity and Liabilities (Total) |
133,960.00 | 136,463.00 | 135,115.00 | 147,680.00 | |
Shares (Common) |
1,767.88 | 1,766.73 | 1,767.07 | 1,767.51 | |
Shareholders Equity (Tangible) |
(91,509.00) | (93,055.00) | (90,546.00) | (98,990.00) | |
Net Debt |
62,267.00 | 63,467.00 | 64,253.00 | 70,129.00 | |
Total Debt |
67,496.00 | 72,858.00 | 70,822.00 | 80,903.00 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026